Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide and a significant public health issue. MASLD may progress to liver cirrhosis and/or hepatocellular carcinoma. Although previous evidence suggests that aspirin has antisteatotic and antifibrotic effects on the liver, a randomized controlled trial assessing long-term efficacy and safety of aspirin in MASLD patients has yet to be conducted. This study aims to conduct a randomized controlled trial to evaluate the efficacy of aspirin in treating MASLD.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 18 years of age or older
• Diagnosed with MASLD, which is defined by the Delphi consensus, with at least one out of five cardiometabolic criteria
Locations
Other Locations
Taiwan
Taichung Veterans General Hospital
RECRUITING
Taichung
Contact Information
Primary
Teng-Yu Lee, MD, MBA, PhD
tylee@vghtc.gov.tw
+886423592525
Time Frame
Start Date: 2025-05-05
Estimated Completion Date: 2032-12-31
Participants
Target number of participants: 120
Treatments
Active_comparator: Aspirin arm
Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo
Placebo_comparator: Placebo arm
Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo
Related Therapeutic Areas
Sponsors
Leads: Taichung Veterans General Hospital